Secondary landmark analysis of the phase 3 IMROZ trial in transplant-ineligible newly diagnosed multiple myeloma: isatuximab added to VRd then Rd gave higher MRD negativity and MRD-negative CR rates than VRd/Rd at end of induction and in maintenance, up to 60 months.
RCT
Orlowski et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study